isosorbide-5-mononitrate has been researched along with Infarct, Lacunar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bath, PM; Doubal, F; Mhlanga, I; Montgomery, AA; Oatey, K; Wardlaw, JM; Woodhouse, LJ | 1 |
| Bamford, J; Bath, PM; Cvoro, V; Doubal, FN; England, T; Hassan, A; Heye, AK; Mhlanga, II; Montgomery, A; O'Brien, JT; Oatey, K; Roffe, C; Sprigg, N; Wardlaw, JM; Werring, DJ; Woodhouse, LJ | 1 |
2 trial(s) available for isosorbide-5-mononitrate and Infarct, Lacunar
| Article | Year |
|---|---|
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
Topics: Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Middle Aged; Prospective Studies; Stroke; Stroke, Lacunar | 2023 |
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Male; Middle Aged; Quality of Life; Stroke; Stroke, Lacunar; Treatment Outcome | 2023 |